ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1210

Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort

Gema María Lledó Ibáñez1, Jorge Álvarez-Troncoso2, Borja del Carmelo Gracia Tello3, Sergio Prieto-Gonzalez4, Elena Martínez Robles5, Diana Cristina-Varela6, Sebastián Molina-Ríos7, Luis Sáez Comet8, Eiman Soliman9, Franklin Uguña10, Miguel Antonio Mesa11, Miguel Martín Cascón12, Tânia Santiago13, Grace-Jimena Santamaría-Peñaloza14, Tsvetoslav Georgiev15, Santiago Bernal-Macias16, Begoña Marí-Alfonso17, Jesus Ballano Rodríguez-Solís18, Sally Patricia Pino Hernández19, Jacek Olas20, Juan Manuel Mosquera Angarita21, Elena García- Guijarro22, Isabel Perales Fraile23, Mayka Freire Dapena24, Iván Pérez de Pedro25, Luis Adrián Viteri Noël26 and Eduardo Ramos ibáñez27, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital Universitario La Paz, Madrid, Madrid, Spain, 3Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 4Hospital Clinic, Barcelona, Catalonia, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, 7Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 8Hospital Universitario Miguel Servet, Zaragoza, Spain, 9Alexandria Faculty of Medicine, Alexandria, Egypt, 10Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, 11Universidad Pontificia Bolivariana, Medellin, Colombia, 12Hospital General Universitario Morales Meseguer, Murcia, Spain, 13ULS de Coimbra, Coimbra, Portugal, 14Hospital Metropolitano, Quito, Ecuador, 15Hospital St. Marina, Varna, Varna, Bulgaria, 16Hospital Universitario San Ignacio, Bogotá, Colombia, 17Hospital Universitario Parc Taulí, Barcelona, Spain, 18Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, 19Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, 20MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, 21Hospital Sant Joan de Déu, Barcelona, Spain, 22Hospital Universitario Infanta Cristina, Madrid, Spain, 23Hospital Universitario Infanta Sofía, Madrid, Spain, 24Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, 25Hospital Regional Universitario de Málaga, Málaga, Spain, 26Hospital Universitario Ramón y Cajal, Madrid, Spain, 27Capillary.io, Zaragoza, Aragon, Spain

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Bioinformatics, Biomarkers, Myopathies, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains limited, partly due to variability in interpretation. Artificial intelligence (AI)-based software offers the potential for objective, standardized capillaroscopic analysis. The CapIAMI project aimed to explore the role of automated NVC evaluation in IIM patients across a large international cohort.

Methods: We conducted an ambispective, observational, international, multicenter study including patients diagnosed with IIM according to established criteria. Standardized NVC images were analyzed using Capillary.io, an AI-based platform extracting quantitative microvascular parameters. Clinical data, laboratory values (CPK, aldolase, LDH, CRP, ESR, and ferritin), and autoantibody profiles were collected at the time of NVC. Disease activity was determined based on clinical evaluation. Predictive models were developed using machine learning algorithms, with performance assessed by cross-validation metrics.

Results: A total of 272 IIM patients from 25 centers were included. The median age was 58.0 years (IQR 41.3–67.0), and 68.2 % were female. Ethnic distribution was 56.2 % Caucasian, 37.7 % Latin American, and 6.0 % other groups. Dermatomyositis was the predominant subtype (53.7 %), followed by antisynthetase syndrome (15.8 %) and overlap myopathy (11.8 %) (Table 1). Clinically active disease was present in 49.3 % of patients. The most frequent active manifestations were myositis (80.5 %), cutaneous involvement (42.7 %), articular symptoms (29.3 %) and interstitial lung disease (ILD) (24.26%) (Table 1).Patients with active disease exhibited significantly higher serum CK and aldolase, elevated CRP (all p < 0.05) and increased prevalence of ILD and late-scleroderma NVC pattern (both p < 0.001). Autoantibody profiles are detailed in Table 2. The most prevalent specificities were anti–Ro-52 (31.6 %), anti–Mi-2 (19.9 %) and anti–PM/Scl (13.2 %), with lesser frequencies for other myositis‐specific and myositis‐associated antibodies.Combining AI-derived capillaroscopic metrics with laboratory biomarkers yielded an overall precision of 0.746 in cross-validated predictive models. Capillary tortuosity, ramification abnormalities, megacapillary presence and hemorrhagic patterns constituted the principal predictive features, with capillary ramification (p = 0.005) and average limb width (p = 0.026) remaining independent predictors. UMAP embedding of these features demonstrated clear segregation of early-, active- and late-scleroderma–like patterns from non-specific/normal patterns (Fig. 1).

Conclusion: Automated NVC analysis combined with conventional laboratory biomarkers improves the prediction of disease activity in IIM patients. These preliminary findings underscore the added value of standardized capillaroscopic evaluation as a complementary tool in clinical practice. Further validation in larger cohorts is needed to confirm and expand these observations.

Supporting image 1Figure 1. UMAP projection of capillaroscopic variables from CapIAMI patients. Each dot represents an individual capillaroscopy, coloured by capillaroscopic pattern and shaped by IIM subtype. The figure shows distinct clustering based on microvascular characteristics, supporting the potential of AI-assisted stratification in idiopathic inflammatory myopathies.

Supporting image 2Table 1. Cohort & Key Clinical Features

Supporting image 3Table 2. Autoantibody Positivity


Disclosures: G. Lledó Ibáñez: None; J. Álvarez-Troncoso: None; B. Gracia Tello: None; S. Prieto-Gonzalez: None; E. Martínez Robles: None; D. Cristina-Varela: None; S. Molina-Ríos: None; L. Sáez Comet: None; E. Soliman: None; F. Uguña: None; M. Mesa: None; M. Martín Cascón: None; T. Santiago: None; G. Santamaría-Peñaloza: None; T. Georgiev: None; S. Bernal-Macias: None; B. Marí-Alfonso: None; J. Rodríguez-Solís: None; S. Pino Hernández: Pfizer, 5; J. Olas: None; J. Mosquera Angarita: None; E. García- Guijarro: None; I. Perales Fraile: None; M. Freire Dapena: None; I. Pérez de Pedro: None; L. Viteri Noël: None; E. Ramos ibáñez: None.

To cite this abstract in AMA style:

Lledó Ibáñez G, Álvarez-Troncoso J, Gracia Tello B, Prieto-Gonzalez S, Martínez Robles E, Cristina-Varela D, Molina-Ríos S, Sáez Comet L, Soliman E, Uguña F, Mesa M, Martín Cascón M, Santiago T, Santamaría-Peñaloza G, Georgiev T, Bernal-Macias S, Marí-Alfonso B, Rodríguez-Solís J, Pino Hernández S, Olas J, Mosquera Angarita J, García- Guijarro E, Perales Fraile I, Freire Dapena M, Pérez de Pedro I, Viteri Noël L, Ramos ibáñez E. Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/artificial-intelligence-based-capillaroscopy-and-laboratory-biomarkers-to-predict-disease-activity-in-idiopathic-inflammatory-myopathies-preliminary-data-from-the-capiami-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/artificial-intelligence-based-capillaroscopy-and-laboratory-biomarkers-to-predict-disease-activity-in-idiopathic-inflammatory-myopathies-preliminary-data-from-the-capiami-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology